Smart scans and DNA tests guide lymphoma treatment
NCT ID NCT06069830
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new way to treat a rare type of nasal lymphoma (NK/T cell lymphoma) by using PET scans and blood tests for the Epstein-Barr virus to decide the best treatment plan. About 89 newly diagnosed patients will receive a combination of chemotherapy, radiation, and immunotherapy tailored to their test results. The goal is to see if this personalized approach can improve how long patients live without their cancer coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pegaspargase, etoposide, dexamethasone, and PD-1 monoclonal antibody
- What this could lead to
- If successful, this approach could lead to more personalized and effective treatment for localized nasal NK/T cell lymphoma, potentially improving survival rates.
- What could go wrong
- This is a small, early-phase study (89 participants) without a control group, so results may not be definitive. The treatment involves chemotherapy and immunotherapy, which carry risks like infection and organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NK-T-CELL LYMPHOMA, EXTRANODAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital
RECRUITINGShanghai, Shanghai Municipality, 200020, China